# ProQR Therapeutics N.V. share price today (ProQR Therapeutics N.V., PRQR)

> ProQR Therapeutics N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PRQR · Healthcare · Biotechnology · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/prqr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $1.37 (−50.2% in a year)
- Revenue (Jun 2026): $8.8 M (+120.4% on a year ago)
- Profit (Jun 2026): −$8.7 M
- ROE: −85%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the ProQR Therapeutics N.V. share price today? ProQR Therapeutics N.V.'s share price was $1.37 at the close on 3 November 2026. That is 18.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $2, and at that close it sat 8% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 6 weeks running. Over the last 1 year the share price moved −41% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does ProQR Therapeutics N.V. pay? ProQR Therapeutics N.V. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is ProQR Therapeutics N.V. on? ProQR Therapeutics N.V. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is ProQR Therapeutics N.V. profitable? ProQR Therapeutics N.V. posted a net loss of $8.7 M in the Jun 2026 quarter. The full FY25 year was a loss of $42.2 M. That loss is 99.6% of the quarter's revenue. The same quarter a year earlier lost $12.2 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does ProQR Therapeutics N.V. make, and is it growing? ProQR Therapeutics N.V. reported $8.8 M of revenue in the Jun 2026 quarter, +120.4% on the same quarter a year earlier. Over 4 years it has grown 61.9% a year on average. The last full year, FY25, came in at $16.3 M. The last four reported quarters add to $18.4 M. FY25 revenue was $16.3 M, −16.4% on the year before. Recent pace: the last four quarters grew +10.6% on average, against 61.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +7.5%, against +8.1% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does ProQR Therapeutics N.V. keep? ProQR Therapeutics N.V. has almost no sales yet: FY25 revenue was $16.3 M. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is ProQR Therapeutics N.V.'s profit turning into cash? ProQR Therapeutics N.V.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $52.8 M of cash, against −$42.2 M of profit. After $1.0 M of spending on assets, free cash was −$53.8 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does ProQR Therapeutics N.V.'s cash go? ProQR Therapeutics N.V. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.8 M on assets over the last 3 years. Averaged over those years that is 7.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $3.8 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is ProQR Therapeutics N.V.'s P/E ratio, and how does it compare with its own history? ProQR Therapeutics N.V. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values ProQR Therapeutics N.V. at 11.8× its FY25 revenue of $16.3 M. The P/E comes back here once profit turns positive. ## Is the ProQR Therapeutics N.V. business getting better or worse? ProQR Therapeutics N.V.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does ProQR Therapeutics N.V. earn on its capital? ProQR Therapeutics N.V. earned a ROE of −85% in FY25. That is up from a low of −97% in FY22. Its return on capital used (ROIC) is 35.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. The key test, return on capital used minus the cost of capital: −30.0% − 5.7% = −35.7 percentage points. The 5.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does ProQR Therapeutics N.V. have too much debt? ProQR Therapeutics N.V. has total debt of $15.3 M against shareholder equity of $79.5 M as of Jun 2026, so its debt is 0.19× its equity, which is very little. Year by year, that ratio went from 0.53 in FY21 to 0.32 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the ProQR Therapeutics N.V. shareholding pattern? We have no ownership or short-position figures for ProQR Therapeutics N.V., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 3.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is ProQR Therapeutics N.V. from balance-sheet trouble? For ProQR Therapeutics N.V., the Z-score is −3.28. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −3.28 is inside the danger zone, so the balance sheet is a real risk. ## How does ProQR Therapeutics N.V. rank in its industry? There is no score against its industry: ProQR Therapeutics N.V. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is ProQR Therapeutics N.V. compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to ProQR Therapeutics N.V. in size? ProQR Therapeutics N.V. is the 195th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: AC Immune SA, Artiva Biotherapeutics, Inc. and Cartesian Therapeutics, Inc. Just below it: Compugen, Niagen Bioscience, Inc. and Upstream Bio, Inc. ### Biotechnology companies close in size

1. [AC Immune SA](https://www.sectoralpha.in/us/stocks/aciu) $208 million
2. [Artiva Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/artv) $205 million
3. [Cartesian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/rnac) $194 million
4. ProQR Therapeutics N.V. $193 million
5. [Compugen Ltd.](https://www.sectoralpha.in/us/stocks/cgen) $190 million
6. [Niagen Bioscience, Inc.](https://www.sectoralpha.in/us/stocks/nage) $187 million
7. [Upstream Bio, Inc.](https://www.sectoralpha.in/us/stocks/upb) $186 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

## What else do people ask about ProQR Therapeutics N.V.? ### What were ProQR Therapeutics N.V.'s latest quarterly results? ProQR Therapeutics N.V. reported revenue of $8.8 M and a net loss of $8.7 M for the Jun 2026 quarter. Earnings per share were −$0.08. The operating margin was −100.7%, 207.5 percentage points higher than a year earlier (as of 3 November 2026). ### What is ProQR Therapeutics N.V.'s profit? ProQR Therapeutics N.V. earned −$8.7 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was −$42.2 M. The operating margin was −100.7% in the latest quarter (as of 3 November 2026). ### What is ProQR Therapeutics N.V.'s market cap? ProQR Therapeutics N.V.'s market capitalisation is $193 M at a stock price of $1.37. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is ProQR Therapeutics N.V. performing? ProQR Therapeutics N.V.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 6 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will ProQR Therapeutics N.V.'s stock price go up? This page does not forecast ProQR Therapeutics N.V.'s stock price. What it shows instead: the stock price is $1.37. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### What could break the ProQR Therapeutics N.V. story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is ProQR Therapeutics N.V. a stock worth studying right now? What the numbers show: ProQR Therapeutics N.V.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.